Ming Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ming Shen has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Biao Ma
State Key Laboratory of Plant Genomics (Q.L., X.L., Q.S., H.C., W.W., J.T., X.B., M.S., B.M., W.Z., S.C., J.Z.) and State Key Laboratory of Molecular Developmental Biology (S.L., G.S.), Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China
1 shared publication- Bo Wang
Division of General Internal Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
1 shared publication Brian H Crawford
Division of Pediatric Cardiology, Department of Pediatrics, Emory University School of Medicine, 1648 Pierce Dr NE, Atlanta, GA 30307, USA
1 shared publicationDesheng Liang
1 shared publicationDongxiao Li
1 shared publicationGuang-Hou Shui
State Key Laboratory of Plant Genomics (Q.L., X.L., Q.S., H.C., W.W., J.T., X.B., M.S., B.M., W.Z., S.C., J.Z.) and State Key Laboratory of Molecular Developmental Biology (S.L., G.S.), Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China
1 shared publication
Latest Publications
- Open Access
- 16 November 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (12) , 1-11
TMEM116 is required for lung cancer cell motility and metastasis through PDK1 signaling pathway
Transmembrane protein (TMEM) is a family of protein that spans cytoplasmic membranes and allows cell–cell and cell–environment communication. Dysregulation of TMEMs has been observed in multiple cancers. However, little is known about TMEM116 in cancer development. In this study, we demonstrate that TMEM116 is highly expressed in non-small-cell lung cancer (NSCLC) tissues and cell lines. Inactivation of TMEM116 reduced cell proliferation, migration and invasiveness of human cancer cells and suppressed A549 induced tumor metastasis in mouse lungs. In addition, TMEM116 deficiency inhibited PDK1-AKT-FOXO3A signaling pathway, resulting in accumulation of TAp63, while activation of PDK1 largely reversed the TMEM116 deficiency induced defects in cancer cell motility, migration and invasive. Together, these results demonstrate that TMEM116 is a critical integrator of oncogenic signaling in cancer metastasis.
- 16 November 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (12) , 1-11
Open AccessTMEM116 is required for lung cancer cell motility and metastasis through PDK1 signaling pathway
Transmembrane protein (TMEM) is a family of protein that spans cytoplasmic membranes and allows cell–cell and cell–environment communication. Dysregulation of TMEMs has been observed in multiple cancers. However, little is known about TMEM116 in cancer development. In this study, we demonstrate that TMEM116 is highly expressed in non-small-cell lung cancer (NSCLC) tissues and cell lines. Inactivation of TMEM116 reduced cell proliferation, migration and invasiveness of human cancer cells and suppressed A549 induced tumor metastasis in mouse lungs. In addition, TMEM116 deficiency inhibited PDK1-AKT-FOXO3A signaling pathway, resulting in accumulation of TAp63, while activation of PDK1 largely reversed the TMEM116 deficiency induced defects in cancer cell motility, migration and invasive. Together, these results demonstrate that TMEM116 is a critical integrator of oncogenic signaling in cancer metastasis.
- 8 December 2020
- Published by Wolters Kluwer Health in Neurology
- Vol. 95 (23) , e3129-e3137
Analysis of 70 patients with hydrocephalus due to cobalamin C deficiency
Objective To analyze the clinical characteristics of patients with hydrocephalus secondary to cobalamin C (cblC) deficiency and to discuss the optimal strategies for assessing and treating such patients by performing clinical and laboratory studies in 70 patients. Methods A total of 1,211 patients were clinically diagnosed with methylmalonic acidemia (MMA) from 1998 to 2019. Among them, cblC deficiency was confirmed in 70 patients with hydrocephalus by brain imaging and biochemical and genetic analysis. Results Of the 70 patients, 67 (95.7%) had early-onset MMA and homocystinuria. The patients typically had high blood propionylcarnitine and total homocysteine, low methionine, and methylmalonic aciduria. Signs of intracranial hypertension were relatively rare. We measured ventricular dilatation early in the disease by cranial ultrasound and MRI and/or CT. Eighteen different MMACHC mutations, including 4 novel mutations (c.427C>T, c.568insT, c.599G>A, and c.615C>A), were identified biallelically in all 70 patients. c.609G>A was the most frequent mutation, followed by c.658_660del, c.217C>T, and c.567dupT. Three cases were diagnosed by postmortem study. Metabolic therapy, including cobalamin injections supplemented with oral l-carnitine and betaine, was administered in the remaining 67 cases. A ventriculoperitoneal shunt was performed in 36 cases. During the follow-up, psychomotor development, nystagmus, impaired vision, and sunset eyes improved gradually. Conclusion Hydrocephalus is a severe condition with several different causes. In this study, ventriculomegaly was found in 70 patients with cblC deficiency. Early diagnosis, etiologic treatment, and prompt surgical intervention are crucial to improve the prognosis of patients.
- 8 December 2020
- Published by Wolters Kluwer Health in Neurology
- Vol. 95 (23) , e3129-e3137
Analysis of 70 patients with hydrocephalus due to cobalamin C deficiency
Objective To analyze the clinical characteristics of patients with hydrocephalus secondary to cobalamin C (cblC) deficiency and to discuss the optimal strategies for assessing and treating such patients by performing clinical and laboratory studies in 70 patients. Methods A total of 1,211 patients were clinically diagnosed with methylmalonic acidemia (MMA) from 1998 to 2019. Among them, cblC deficiency was confirmed in 70 patients with hydrocephalus by brain imaging and biochemical and genetic analysis. Results Of the 70 patients, 67 (95.7%) had early-onset MMA and homocystinuria. The patients typically had high blood propionylcarnitine and total homocysteine, low methionine, and methylmalonic aciduria. Signs of intracranial hypertension were relatively rare. We measured ventricular dilatation early in the disease by cranial ultrasound and MRI and/or CT. Eighteen different MMACHC mutations, including 4 novel mutations (c.427C>T, c.568insT, c.599G>A, and c.615C>A), were identified biallelically in all 70 patients. c.609G>A was the most frequent mutation, followed by c.658_660del, c.217C>T, and c.567dupT. Three cases were diagnosed by postmortem study. Metabolic therapy, including cobalamin injections supplemented with oral l-carnitine and betaine, was administered in the remaining 67 cases. A ventriculoperitoneal shunt was performed in 36 cases. During the follow-up, psychomotor development, nystagmus, impaired vision, and sunset eyes improved gradually. Conclusion Hydrocephalus is a severe condition with several different causes. In this study, ventriculomegaly was found in 70 patients with cblC deficiency. Early diagnosis, etiologic treatment, and prompt surgical intervention are crucial to improve the prognosis of patients.
- Open Access
- 9 February 2017
- Published by Oxford University Press (OUP) in Plant Physiology
- Vol. 173 (4) , 2208-2224
Selection for a Zinc-Finger Protein Contributes to Seed Oil Increase during Soybean Domestication
Domestication-selective GmZF351 encoding tandem CCCH zinc finger protein promotes seed oil accumulation in soybean.
- 9 February 2017
- Published by Oxford University Press (OUP) in Plant Physiology
- Vol. 173 (4) , 2208-2224
Open AccessSelection for a Zinc-Finger Protein Contributes to Seed Oil Increase during Soybean Domestication
Domestication-selective GmZF351 encoding tandem CCCH zinc finger protein promotes seed oil accumulation in soybean.
- Open Access
- 30 July 2015
- Published by Taylor & Francis in Nanomedicine
- Vol. 10 (22) , 3343-3357
Bioactive Nanoparticles Improve Calcium Handling in Failing Cardiac Myocytes
Aims: To evaluate the ability of N-acetylglucosamine (GlcNAc) decorated nanoparticles and their cargo to modulate calcium handling in failing cardiac myocytes (CMs). Materials & methods: Primary CMs isolated from normal and failing hearts were treated with GlcNAc nanoparticles in order to assess the ability of the nanoparticles and their cargo to correct dysfunctional calcium handling in failing myocytes. Results & conclusion: GlcNAc particles reduced aberrant calcium release in failing CMs and restored sarcomere function. Additionally, encapsulation of a small calcium-modulating protein, S100A1, in GlcNAc nanoparticles also showed improved calcium regulation. Thus, the development of our bioactive nanoparticle allows for a ‘two-hit’ treatment, by which the cargo and also the nanoparticle itself can modulate intracellular protein activity.
- 30 July 2015
- Published by Taylor & Francis in Nanomedicine
- Vol. 10 (22) , 3343-3357
Open AccessBioactive Nanoparticles Improve Calcium Handling in Failing Cardiac Myocytes
Aims: To evaluate the ability of N-acetylglucosamine (GlcNAc) decorated nanoparticles and their cargo to modulate calcium handling in failing cardiac myocytes (CMs). Materials & methods: Primary CMs isolated from normal and failing hearts were treated with GlcNAc nanoparticles in order to assess the ability of the nanoparticles and their cargo to correct dysfunctional calcium handling in failing myocytes. Results & conclusion: GlcNAc particles reduced aberrant calcium release in failing CMs and restored sarcomere function. Additionally, encapsulation of a small calcium-modulating protein, S100A1, in GlcNAc nanoparticles also showed improved calcium regulation. Thus, the development of our bioactive nanoparticle allows for a ‘two-hit’ treatment, by which the cargo and also the nanoparticle itself can modulate intracellular protein activity.